See bevacizumab on Wiktionary
{ "etymology_templates": [ { "args": { "1": "en", "2": "beva-", "3": "-ci-", "4": "-zumab", "qq1": "of unknown origin", "t2": "cardiovascular", "t3": "humanized monoclonal antibody" }, "expansion": "beva- (of unknown origin) + -ci- (“cardiovascular”) + -zumab (“humanized monoclonal antibody”)", "name": "af" } ], "etymology_text": "From beva- (of unknown origin) + -ci- (“cardiovascular”) + -zumab (“humanized monoclonal antibody”).", "head_templates": [ { "args": { "1": "-" }, "expansion": "bevacizumab (uncountable)", "name": "en-noun" } ], "lang": "English", "lang_code": "en", "pos": "noun", "senses": [ { "categories": [ { "kind": "other", "name": "English entries with incorrect language header", "parents": [ "Entries with incorrect language header", "Entry maintenance" ], "source": "w" }, { "kind": "other", "name": "English terms interfixed with -ci-", "parents": [], "source": "w" }, { "kind": "other", "name": "English terms prefixed with beva-", "parents": [], "source": "w" }, { "kind": "other", "name": "English terms suffixed with -zumab", "parents": [], "source": "w" }, { "kind": "other", "name": "Pages with 1 entry", "parents": [], "source": "w" }, { "kind": "other", "name": "Pages with entries", "parents": [], "source": "w" }, { "kind": "topical", "langcode": "en", "name": "Pharmaceutical drugs", "orig": "en:Pharmaceutical drugs", "parents": [ "Drugs", "Matter", "Pharmacology", "Chemistry", "Nature", "Biochemistry", "Medicine", "Sciences", "All topics", "Biology", "Healthcare", "Fundamental", "Health", "Body" ], "source": "w" } ], "glosses": [ "An anticancer drug that is a genetically engineered monoclonal antibody administered intravenously to slow or inhibit tumor growth especially in some metastatic forms of cancer (such as colorectal cancer). It acts by binding to and inhibiting the activity of vascular endothelial growth factor, a protein that promotes the growth of new blood vessels which supply a spreading tumor. It is marketed under the trademark Avastin." ], "id": "en-bevacizumab-en-noun-nry2cVxv", "links": [ [ "pharmacology", "pharmacology" ], [ "anticancer", "anticancer" ], [ "genetically engineered", "genetically engineered" ], [ "monoclonal antibody", "monoclonal antibody" ], [ "intravenously", "intravenously" ], [ "metastatic", "metastatic" ], [ "vascular endothelial growth factor", "vascular endothelial growth factor" ], [ "blood vessel", "blood vessel" ] ], "raw_glosses": [ "(pharmacology) An anticancer drug that is a genetically engineered monoclonal antibody administered intravenously to slow or inhibit tumor growth especially in some metastatic forms of cancer (such as colorectal cancer). It acts by binding to and inhibiting the activity of vascular endothelial growth factor, a protein that promotes the growth of new blood vessels which supply a spreading tumor. It is marketed under the trademark Avastin." ], "tags": [ "uncountable" ], "topics": [ "medicine", "pharmacology", "sciences" ], "wikipedia": [ "bevacizumab" ] } ], "sounds": [ { "ipa": "/ˌbɛv.əˈsɪz.ʊˌmæb/", "tags": [ "General-American" ] } ], "word": "bevacizumab" }
{ "etymology_templates": [ { "args": { "1": "en", "2": "beva-", "3": "-ci-", "4": "-zumab", "qq1": "of unknown origin", "t2": "cardiovascular", "t3": "humanized monoclonal antibody" }, "expansion": "beva- (of unknown origin) + -ci- (“cardiovascular”) + -zumab (“humanized monoclonal antibody”)", "name": "af" } ], "etymology_text": "From beva- (of unknown origin) + -ci- (“cardiovascular”) + -zumab (“humanized monoclonal antibody”).", "head_templates": [ { "args": { "1": "-" }, "expansion": "bevacizumab (uncountable)", "name": "en-noun" } ], "lang": "English", "lang_code": "en", "pos": "noun", "senses": [ { "categories": [ "English entries with incorrect language header", "English lemmas", "English nouns", "English terms interfixed with -ci-", "English terms prefixed with beva-", "English terms suffixed with -zumab", "English uncountable nouns", "Pages with 1 entry", "Pages with entries", "en:Pharmaceutical drugs" ], "glosses": [ "An anticancer drug that is a genetically engineered monoclonal antibody administered intravenously to slow or inhibit tumor growth especially in some metastatic forms of cancer (such as colorectal cancer). It acts by binding to and inhibiting the activity of vascular endothelial growth factor, a protein that promotes the growth of new blood vessels which supply a spreading tumor. It is marketed under the trademark Avastin." ], "links": [ [ "pharmacology", "pharmacology" ], [ "anticancer", "anticancer" ], [ "genetically engineered", "genetically engineered" ], [ "monoclonal antibody", "monoclonal antibody" ], [ "intravenously", "intravenously" ], [ "metastatic", "metastatic" ], [ "vascular endothelial growth factor", "vascular endothelial growth factor" ], [ "blood vessel", "blood vessel" ] ], "raw_glosses": [ "(pharmacology) An anticancer drug that is a genetically engineered monoclonal antibody administered intravenously to slow or inhibit tumor growth especially in some metastatic forms of cancer (such as colorectal cancer). It acts by binding to and inhibiting the activity of vascular endothelial growth factor, a protein that promotes the growth of new blood vessels which supply a spreading tumor. It is marketed under the trademark Avastin." ], "tags": [ "uncountable" ], "topics": [ "medicine", "pharmacology", "sciences" ], "wikipedia": [ "bevacizumab" ] } ], "sounds": [ { "ipa": "/ˌbɛv.əˈsɪz.ʊˌmæb/", "tags": [ "General-American" ] } ], "word": "bevacizumab" }
Download raw JSONL data for bevacizumab meaning in All languages combined (2.3kB)
This page is a part of the kaikki.org machine-readable All languages combined dictionary. This dictionary is based on structured data extracted on 2024-12-21 from the enwiktionary dump dated 2024-12-04 using wiktextract (d8cb2f3 and 4e554ae). The data shown on this site has been post-processed and various details (e.g., extra categories) removed, some information disambiguated, and additional data merged from other sources. See the raw data download page for the unprocessed wiktextract data.
If you use this data in academic research, please cite Tatu Ylonen: Wiktextract: Wiktionary as Machine-Readable Structured Data, Proceedings of the 13th Conference on Language Resources and Evaluation (LREC), pp. 1317-1325, Marseille, 20-25 June 2022. Linking to the relevant page(s) under https://kaikki.org would also be greatly appreciated.